Biosev S.A.

Av. Brig. Faria Lima,1355 11°andar 01452-919 São Paulo SP Brasil

T 55 11 3092 5200

F 55 11 3092 5373 www.biosev.com

São Paulo, August 25th, 2020.

TO

B3 S.A. - BRASIL, BOLSA, BALCÃO

c/o Mrs. Ana Lúcia da Costa Pereira.

Superintendência de Acompanhamento de Empresas e Ofertas de Valores Mobiliários de Renda Variável

With copy to

CVM - COMISSÃO DE VALORES MOBILIÁRIOS

Mr. Fernando Soares Vieira - Superintendência de Relações com Empresas

Mr. Francisco José Bastos Santos - Superintendência de Relações com o Mercado e Intermediários

Reference: Atypical Stock Oscillation - Response to B3 Letter 621/2020-SLS.

BIOSEV S.A., a publicly-held company, with its registered office at Avenida Brigadeiro Faria Lima, 1,355, 11th floor, Pinheiros, São Paulo / SP, enrolled at CNPJ under no. 15.527.906 / 0001-36, registered with the Brazilian Securities and Exchange Commission ("CVM") under CVM code 22845 ("Company"), by its Chief Financial and Investor Relations Officer hereby presents the clarifications requested in Letter No. 621/2020-SLS ("B3 Letter"), which questioned the Company about the knowledge of any fact that would have caused the atypical oscillation of the price of its shares ("BSEV3"), in the period between 08.11.2020 and 08.24.2020, the content of which is transcribed as follows:

"In view of the latest fluctuations registered in relation to the shares issued by this company, the number of trades and the amount traded, as shown below, we request to be informed, by 08/25/2020, if there is any fact that you are aware of that can justify them."

ON Shares

Prices (R$ per share)

Date

Opening

Minimum

Maximum

Average

Last

Oscil.

Nº

Amount

Volume (R$)

%

neg.

08/11/2020

3,56

3,52

3,60

3,56

3,53

-0,84

104

34.300

122.272,00

08/12/2020

3,53

3,37

3,53

3,44

3,49

-1,13

85

23.800

81.890,00

08/13/2020

3,55

3,39

3,59

3,47

3,40

-2,57

74

42.200

146.478,00

08/14/2020

3,37

3,37

3,50

3,41

3,39

-0,29

76

34.600

118.051,00

08/17/2020

3,40

3,16

3,52

3,31

3,34

-1,47

188

100.000

331.395,00

08/18/2020

3,33

3,24

3,49

3,37

3,39

1,49

83

33.700

113.588,00

08/19/2020

3,40

3,31

3,40

3,35

3,34

-1,47

57

16.800

56.253,00

08/20/2020

3,22

3,22

3,42

3,28

3,39

1,49

67

16.900

55.505,00

08/21/2020

3,45

3,32

3,45

3,38

3,43

1,17

67

21.000

70.988,00

08/24/2020*

3,43

3,36

4,11

3,85

4,04

17,78

657

466.400

1.798.555,00

* Updated until 12h44 pm.

  1. In response to the B3 Letter, the Company informs that it is not aware of any material act or fact related to the Company not disclosed to the market that could justify the atypical fluctuations mentioned above.
  2. Nevertheless, the Company reports below the facts of which it is aware:
    1. In the time period mentioned in the B3 Letter, sugar prices in Brazilian reais (as verified in the prices of NY#11 pegged to the exchange rate) and ethanol prices (as verified in the Esalq and BMF prices) had a positive fluctuation.
    2. As informed in several material facts since 2018, as well as in response to (i) B3 letters no. 1813/2018-SAE, no. 1815/2018-SAE and no. 10/2020-SLS, released in the form of Notice to the Market and dated October 23, 2018, October 24, 2018 and January 8, 2020, respectively; and (ii) CVM - Comissão de Valores Mobiliários (Brazilian Securities and Exchange Commission) letter no. 349/2018/CVM/SEP/GEA-2, released in the form of Notice to the Market on November 30, 2018; the Company clarifies that it continues to focus on its operational competitiveness program, which includes reviewing potential strategic alternatives related to its asset portfolio, aiming at increasing its cash generation and strengthening its capital structure. These alternatives may involve a wide range of opportunities, including optimization of assets, eventual strategic partnerships, associations, joint ventures, corporate reorganizations and/or disposals of assets, as well as diversification of its sources of financing and/or renewal and extension of its financing indebtedness.
      Notwithstanding the paragraph above, the Company clarifies that there is no binding commitment or agreement regarding any such potential strategic alternatives, no corporate approval to process with any potential strategic alternative, nor there is assurance about the implementation of any such alternatives.
  4. Provided the necessary information, the Company remains available for any further clarification that may be deemed necessary.

Regards,

BIOSEV S.A.

Leonardo Oliveira D'Elia

Chief Financial and Investor Relations Officer

Attachments

  • Original document
  • Permalink

Disclaimer

Biosev SA published this content on 25 August 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 August 2020 00:16:08 UTC